Goldman cites a “positive surprise” for GSK ahead of ACIP meeting on RSV shot

Goldman Sachs said Monday that GSK (NYSE:GSK) is set for a ‘positive surprise’ this week as a CDC Advisory Committee is scheduled to discuss whether to broaden the recommendation for Arexvy, the British drugmaker’s vaccine for respiratory syncytial virus (RSV).